Current Pipeline
- Home
- Technology
-
-
TECHNOLOGY
- What We do
-
-
What is AmyTrap
-
AmyTrap in Action
-
AmyTrapper
-
Current Pipeline
We are Here
RTL's current focus is on developing small molecules to treat Alzheimer's disease.
Recombinant Technologies, LLC
1090, Meriden Waterbury Road, Suite1
06410, USA
1090, Meriden Waterbury Road, Suite1
06410, USA
Tel: + (203)271-3125(T), Fax: + (203)271-3126
E-mail: contact@recombtech.com
- Sundaram RK, Kasinathan C, Stein S, Sundaram P.Detoxification depots for beta amyloid Readmore
- Plasma lipids and lipoprotein profile in coronary heart disease and in healthy volunteers in South India. Readmore
- Novel detox gel depot sequesters β- Amyloid Peptides in a mouse model of Alzheimer's disease. Readmore
- Patents on potential drugs to treat Alzheimer's Disease: Special emphasis on small peptides. Readmore
http://www.alzforum.org/ Click Here
More News From Nice's Preclinical, Genetics, and Basic Science Fronts Click here
Heavyweights Fend Off Dementia; Featherweights Go Down Click Here.
FDA Offers Support for Alzheimer's and Parkinson's Biomarkers Click Here
Copyright 2014-2016 Recombinant Technologies | All Rights Reserved | Powered by i-Grandee Software Technologies Pvt.Ltd